Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

46
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
46

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-Term Outcomes of In-Utero Xylazine Exposure in Infants With NOWS.

Hospital pediatrics·2026
Same author

Possible alignment of the EU BSE surveillance with the new WOAH provisions.

EFSA journal. European Food Safety Authority·2026
Same author

Vitamin A-associated onycholysis.

Proceedings (Baylor University. Medical Center)·2025
Same author

Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models.

Kidney international·2025
Same author

Evaluation of a fluidised catalytic cracking co-processing method for the production of renewable fuels using Category 3 animal fat and used cooking oils.

EFSA journal. European Food Safety Authority·2025
Same author

BIOHAZ scientific opinion on the equivalence of an alternative heat treatment process of feathers and down.

EFSA journal. European Food Safety Authority·2025

Related Experiment Video

Updated: Jun 5, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K

Bevacizumab-induced subungual hemorrhage.

Jacob J Owen1, Sloan Long, Kimberly Mullinax

  • 1Texas A&M School of Medicine, Dallas, Texas, USA.

Dermatology Online Journal
|December 16, 2024
PubMed
Summary

This study reports a potential new side effect of bevacizumab treatment for wet age-related macular degeneration: subungual hemorrhage. This fingernail discoloration may be an underreported adverse event of this common therapy.

Area of Science:

  • Ophthalmology
  • Oncology
  • Dermatology

Background:

  • Exudative (wet) age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is an effective treatment for wet AMD.
  • Known skin-related side effects of bevacizumab include rash, mucosal hemorrhage, and hemorrhagic ulcers.

Observation:

  • A 71-year-old female patient receiving intravitreal bevacizumab for bilateral AMD developed fingernail discoloration resembling bruising.
  • This subungual hemorrhage occurred during six months of continuous bevacizumab therapy.
  • No prior reports link bevacizumab directly to subungual hemorrhage exist.

Findings:

  • The patient's subungual hemorrhage is hypothesized to be an adverse effect of bevacizumab therapy.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

9.8K

Related Experiment Videos

Last Updated: Jun 5, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

9.8K
  • This finding suggests that subungual hemorrhage may be an underreported side effect of bevacizumab.
  • The mechanism may be related to bevacizumab's anti-VEGF activity, similar to other agents.

    • Implications:

    • Clinicians should be aware of the potential for bevacizumab-induced subungual hemorrhage in patients undergoing treatment for AMD.
    • Further investigation is warranted to confirm this association and elucidate the underlying mechanisms.
    • Monitoring for dermatological side effects, including nail changes, is crucial during bevacizumab therapy.